3TC nucleoside analog data

BCHXF (Laval, Québec) announced positive preliminary results of two North American Phase II/III trials involving 618 patients taking 3TC in combination with AZT. The company reported a 23-24 percent dropout rate for the trials, attributing dropouts to adverse publicity generated by the FIAU disaster. The company had previously reported data from two European trials (See BioCentury, Nov. 21).

A study of 364 patients with CD4 counts of 200-500 who had previously received less than four weeks of AZT therapy compared the combination of high dose (300 mg twice a day) 3TC with AZT to low dose (150 mg twice a day) 3TC plus AZT, to AZT alone and to 3TC alone. ...